Medicina clinica (English ed.)最新文献

英文中文

Diffuse idiopathic pulmonary neuroendocrine cell hiperplasia: a rare cause of lung nodules 弥漫性特发性肺神经内分泌细胞疱疹：肺结节的罕见病因

Medicina clinica (English ed.)

Pub Date : 2024-09-04 DOI: 10.1016/j.medcle.2024.03.020

引用次数: 0

Tinea manuum 牛皮癣

Medicina clinica (English ed.)

Pub Date : 2024-09-04 DOI: 10.1016/j.medcle.2023.12.029

引用次数: 0

Percutaneous embolectomy in high-risk acute pulmonary embolism 高危急性肺栓塞的经皮栓子切除术

Medicina clinica (English ed.)

Pub Date : 2024-09-04 DOI: 10.1016/j.medcle.2024.01.042

引用次数: 0

Effectiveness of tixagevimab/cilgavimab in reducing SARS-CoV-2 infections, hospitalizations and mortality in inmunocompromised patients 替沙吉单抗/西格维单抗在降低免疫力低下患者 SARS-CoV-2 感染率、住院率和死亡率方面的效果

Medicina clinica (English ed.)

Pub Date : 2024-09-04 DOI: 10.1016/j.medcle.2024.03.018

Introduction

Inmunocompromised people have higher SARS-CoV-2 morbi-mortality and they are subsidiary to receive pre-exposure prophylaxis. The objective of this study is to evaluate the effectiveness of tixagevimab/cilgavimab (Evusheld) in preventing SARS-CoV-2 infections, hospitalizations and mortality in immunocompromised patients.

Materials and methods

119 immunocompromised people ≥18 years old eligible of receiving Evusheld were followed for 6 months. People with previous SARS-CoV-2 infection or incomplete vaccination regimen were exluded. A total of 19 people who received Evusheld were matched by propensity score, using a 1:1 ratio, with another 19 people who did not receive Evusheld.

Sociodemographic, related to SARS-CoV-2 risk factors and related to immunosuppression variables were included. The dependent variables were infection, hospitalization, and mortality related to SARS-CoV-2.

Statistical analyzes were performed using SPSS Statistics 19.0, STATA 11.0, and the R statistical package.

Results

In total, 4 people in the Evusheld group and 11 in the control group had SARS-CoV-2 infection, showing an incidence rate of 3.87 and 13.62 per 100 person-months, respectively. The HR (Hazard Ratio) was 0.29 (95% CI = 0.09−0.90) for SARS-CoV-2 infection, 0.37 (0.07−1.92) for SARS-CoV-2 hospitalization and, 0.23 (0.03−2.09) for SARS-CoV-2 mortality in the Evusheld group compared to control group.

Conclusions

This study demonstrates that Evusheld reduces the SARS-CoV-2 infections.

导言：免疫功能低下者的 SARS-CoV-2 死亡率较高，他们是接受暴露前预防的辅助人群。本研究的目的是评估替沙吉单抗/西格维单抗（Evusheld）在预防免疫功能低下患者 SARS-CoV-2 感染、住院和死亡方面的有效性。既往感染过 SARS-CoV-2 或疫苗接种程序不完整者除外。社会人口学变量、与SARS-CoV-2相关的危险因素变量和与免疫抑制相关的变量均包括在内。统计分析使用 SPSS Statistics 19.0、STATA 11.0 和 R 统计软件包进行。结果 Evusheld 组共有 4 人感染了 SARS-CoV-2，对照组共有 11 人感染了 SARS-CoV-2，发病率分别为每百人月 3.87 例和 13.62 例。与对照组相比，Evusheld 组的 SARS-CoV-2 感染率为 0.29（95% CI = 0.09-0.90），SARS-CoV-2 住院率为 0.37（0.07-1.92），SARS-CoV-2 死亡率为 0.23（0.03-2.09）。

{"title":"Effectiveness of tixagevimab/cilgavimab in reducing SARS-CoV-2 infections, hospitalizations and mortality in inmunocompromised patients","authors":"","doi":"10.1016/j.medcle.2024.03.018","DOIUrl":"10.1016/j.medcle.2024.03.018","url":null,"abstract":"<div><h3>Introduction</h3><div>Inmunocompromised people have higher SARS-CoV-2 morbi-mortality and they are subsidiary to receive pre-exposure prophylaxis. The objective of this study is to evaluate the effectiveness of tixagevimab/cilgavimab (Evusheld) in preventing SARS-CoV-2 infections, hospitalizations and mortality in immunocompromised patients.</div></div><div><h3>Materials and methods</h3><div>119 immunocompromised people ≥18 years old eligible of receiving Evusheld were followed for 6 months. People with previous SARS-CoV-2 infection or incomplete vaccination regimen were exluded. A total of 19 people who received Evusheld were matched by propensity score, using a 1:1 ratio, with another 19 people who did not receive Evusheld.</div><div>Sociodemographic, related to SARS-CoV-2 risk factors and related to immunosuppression variables were included. The dependent variables were infection, hospitalization, and mortality related to SARS-CoV-2.</div><div>Statistical analyzes were performed using SPSS Statistics 19.0, STATA 11.0, and the R statistical package.</div></div><div><h3>Results</h3><div>In total, 4 people in the Evusheld group and 11 in the control group had SARS-CoV-2 infection, showing an incidence rate of 3.87 and 13.62 per 100 person-months, respectively. The HR (Hazard Ratio) was 0.29 (95% CI = 0.09−0.90) for SARS-CoV-2 infection, 0.37 (0.07−1.92) for SARS-CoV-2 hospitalization and, 0.23 (0.03−2.09) for SARS-CoV-2 mortality in the Evusheld group compared to control group.</div></div><div><h3>Conclusions</h3><div>This study demonstrates that Evusheld reduces the SARS-CoV-2 infections.</div></div>","PeriodicalId":74154,"journal":{"name":"Medicina clinica (English ed.)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142315412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Meaning and relevance of paper mills 造纸厂的意义和相关性

Medicina clinica (English ed.)

Pub Date : 2024-09-04 DOI: 10.1016/j.medcle.2024.02.018

引用次数: 0

Identification of NDST1 variant as a cause of intellectual disability 确定 NDST1 变异是导致智力残疾的原因之一

Medicina clinica (English ed.)

Pub Date : 2024-09-04 DOI: 10.1016/j.medcle.2024.03.019

引用次数: 0

Value of the biomarker soluble tyrosine kinase 1 type fms (sFLT-1) in the diagnosis and prognosis of sepsis: a systematic review 生物标志物可溶性酪氨酸激酶1型fms（sFLT-1）在败血症诊断和预后中的价值：系统综述

Medicina clinica (English ed.)

Pub Date : 2024-09-02 DOI: 10.1016/j.medcle.2024.03.014

Introduction

The present systematic review analyses the role of soluble fms-like tyrosine kinase-1 (sFLT-1) as an indirect biomarCker of endothelial dysfunction in sepsis or septic shock from articles published in Pubmed between 2010 and March 2022.

Materials and methods

A systematic review of studies studying sFLT-1 monitoring in intensive care units in adults with sepsis or septic shock vs. controls for sepsis diagnosis and prognosis has been carried out (PROSPERO CRD42023412929 Registry).

Results

The endothelial dysfunction of sepsis is one of the keys to the development of the disease. VEGF binds to sFlt-1 acting as a competitive inhibitor of VEGF signalling in endothelial cells and thus neutralizes its pro-inflammatory effects. Endothelial dysfunction is reflected in increased sFLT-1 levels. High values of sFLT-1 were used for the differential diagnosis of sepsis versus other inflammatory pathologies, septic shock versus other types of shock, were elevated over time, estimation of disease prognosis, correlation with sepsis severity, organ dysfunction, and mortality prediction.

Conclusions

It is evident that sepsis is based on endothelial dysfunction. sFLT-1 is one of the main biomarkers of microvascular alteration and is a predictive diagnostic and prognostic biomarker.

导言本系统综述分析了 2010 年至 2022 年 3 月间发表在 Pubmed 上的文章中可溶性酪氨酸激酶-1（sFLT-1）作为脓毒症或脓毒性休克患者内皮功能障碍的间接生物标记物的作用。材料与方法对重症监护病房中成人脓毒症或脓毒性休克患者与对照组进行 sFLT-1 监测以诊断脓毒症和预后的研究进行了系统性回顾（PROSPERO CRD42023412929 注册）。结果脓毒症的内皮功能障碍是疾病发展的关键之一。血管内皮生长因子与 sFlt-1 结合，成为血管内皮细胞中血管内皮生长因子信号的竞争性抑制剂，从而中和了血管内皮生长因子的促炎作用。内皮功能障碍反映在 sFLT-1 水平的升高上。sFLT-1 的高值可用于鉴别诊断脓毒症与其他炎症性病变、脓毒性休克与其他类型休克、随时间推移而升高、疾病预后估计、与脓毒症严重程度、器官功能障碍的相关性以及死亡率预测。

{"title":"Value of the biomarker soluble tyrosine kinase 1 type fms (sFLT-1) in the diagnosis and prognosis of sepsis: a systematic review","authors":"","doi":"10.1016/j.medcle.2024.03.014","DOIUrl":"10.1016/j.medcle.2024.03.014","url":null,"abstract":"<div><h3>Introduction</h3><p>The present systematic review analyses the role of soluble fms-like tyrosine kinase-1 (sFLT-1) as an indirect biomarCker of endothelial dysfunction in sepsis or septic shock from articles published in Pubmed between 2010 and March 2022.</p></div><div><h3>Materials and methods</h3><p>A systematic review of studies studying sFLT-1 monitoring in intensive care units in adults with sepsis or septic shock vs. controls for sepsis diagnosis and prognosis has been carried out (PROSPERO CRD42023412929 Registry).</p></div><div><h3>Results</h3><p>The endothelial dysfunction of sepsis is one of the keys to the development of the disease. VEGF binds to sFlt-1 acting as a competitive inhibitor of VEGF signalling in endothelial cells and thus neutralizes its pro-inflammatory effects. Endothelial dysfunction is reflected in increased sFLT-1 levels. High values of sFLT-1 were used for the differential diagnosis of sepsis versus other inflammatory pathologies, septic shock versus other types of shock, were elevated over time, estimation of disease prognosis, correlation with sepsis severity, organ dysfunction, and mortality prediction.</p></div><div><h3>Conclusions</h3><p>It is evident that sepsis is based on endothelial dysfunction. sFLT-1 is one of the main biomarkers of microvascular alteration and is a predictive diagnostic and prognostic biomarker.</p></div>","PeriodicalId":74154,"journal":{"name":"Medicina clinica (English ed.)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2387020624003681/pdfft?md5=0a7d827c91a86fc6a32bc28f3c26914f&pid=1-s2.0-S2387020624003681-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142162733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Renal involvement in adults with cystic fibrosis: Study of 89 patients 成人囊性纤维化患者的肾脏受累情况：对 89 名患者的研究

Medicina clinica (English ed.)

Pub Date : 2024-08-31 DOI: 10.1016/j.medcle.2024.03.013

Introduction

We are assisting to an increase in survival rates among individuals with cystic fibrosis (CF). Until now, renal involvement was a minority issue, but with the rise in life expectancy, we will likely see an increase in its prevalence. Our main objective was to assess renal function in CF and study risk factors associated with its deterioration.

Methods

A cross-sectional, retrospective study was conducted, including adults with CF. Clinical, respiratory function, microbiological, blood and urine analysis, and major chronic treatments received were collected.

Results

Eighty nine patients with a mean age of 35 ± 12 years were analyzed. Mean serum creatinine levels were 0.8 ± 0.2 mg/dL. 10.6% had a glomerular filtration rate less than 90 ml/min/1.73 m². No patient showed albuminuria. In multivariate model, only age was an independent risk factor for reduced glomerular filtration (OR 0.344, 95% CI 0.004−0.017, p = 0.002).

Conclusions

11% of CF adults show decreased glomerular filtration, with age being the sole independent risk factor. Vigilance for this uncommon condition is crucial.

导言：我们正在协助提高囊性纤维化（CF）患者的存活率。到目前为止，肾脏受累还只是少数人的问题，但随着预期寿命的延长，肾脏受累的患病率可能会增加。我们的主要目标是评估 CF 患者的肾功能，并研究与肾功能恶化相关的风险因素。研究收集了临床、呼吸功能、微生物、血液和尿液分析，以及接受的主要慢性治疗。平均血清肌酐水平为 0.8 ± 0.2 mg/dL。10.6%的患者肾小球滤过率低于 90 ml/min/1.73 m2。没有患者出现白蛋白尿。在多变量模型中，只有年龄是肾小球滤过率降低的独立危险因素（OR 0.344，95% CI 0.004-0.017，P = 0.002）。警惕这种不常见的疾病至关重要。

{"title":"Renal involvement in adults with cystic fibrosis: Study of 89 patients","authors":"","doi":"10.1016/j.medcle.2024.03.013","DOIUrl":"10.1016/j.medcle.2024.03.013","url":null,"abstract":"<div><h3>Introduction</h3><p>We are assisting to an increase in survival rates among individuals with cystic fibrosis (CF). Until now, renal involvement was a minority issue, but with the rise in life expectancy, we will likely see an increase in its prevalence. Our main objective was to assess renal function in CF and study risk factors associated with its deterioration.</p></div><div><h3>Methods</h3><p>A cross-sectional, retrospective study was conducted, including adults with CF. Clinical, respiratory function, microbiological, blood and urine analysis, and major chronic treatments received were collected.</p></div><div><h3>Results</h3><p>Eighty nine patients with a mean age of 35 ± 12 years were analyzed. Mean serum creatinine levels were 0.8 ± 0.2 mg/dL. 10.6% had a glomerular filtration rate less than 90 ml/min/1.73 m<sup>2</sup>. No patient showed albuminuria. In multivariate model, only age was an independent risk factor for reduced glomerular filtration (OR 0.344, 95% CI 0.004−0.017, p = 0.002).</p></div><div><h3>Conclusions</h3><p>11% of CF adults show decreased glomerular filtration, with age being the sole independent risk factor. Vigilance for this uncommon condition is crucial.</p></div>","PeriodicalId":74154,"journal":{"name":"Medicina clinica (English ed.)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142162729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recurrent Polychondritis as a mimicker of challenging-to-manage allergic asthma 复发性多软骨炎是难以控制的过敏性哮喘的模仿者

Medicina clinica (English ed.)

Pub Date : 2024-08-31 DOI: 10.1016/j.medcle.2024.03.012

引用次数: 0

Perianal basal cell carcinoma 肛周基底细胞癌

Medicina clinica (English ed.)

Pub Date : 2024-08-31 DOI: 10.1016/j.medcle.2024.04.010

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Medicina clinica (English ed.)

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀